ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

NCI To Pilot Text Chat On CancerNet And CIS Sites.

September 29, 2000

Sharon Murphy To Head New Research Center in San Antonio

August 2, 2002

Mail Mixup Delays July 23 Issue

August 6, 1976

New Creatinine Test Raises Questions About Accuracy Of Carboplatin Dosing

October 8, 2010

DCCP Payback System Saving $1 Million Year

December 3, 1982